文/梧桐晓编 2026年3月2日,公司及相关当事人收到中国证监会浙江监管局出具的《行 政处罚事先告知书》（浙处罚字【2026】1 号）,现将相关情况公告如下: 二、《行政处罚事先告知书》的主要内容 浙江向日葵大健康科技股份有限公司、吴少钦先生、李岚女士: 浙江向日葵大健康科技股份有限公司(以下简称向日葵或公司)涉嫌信息披 露违法违规一案,已由我局调查完毕,我局依法拟对你们作出行政处罚。现将我 局拟对你们作出行政处罚所根据的违法事实、理由、依据及你们享有的相关权利 予以告知。 经查明,当事人涉嫌违法的事实如下: 2025年9月22日,向日葵披露《发行股份及支付现金购买资产并募集配套 资金暨关联交易预案》(以下简称《预案》),称公司拟通过发行股份及支付现 金的方式购买漳州兮璞材料科技有限公司(以下简称兮璞材料)100%股权、浙 江贝得药业有限公司 40%股权,并募集配套资金,交易预计构成重大资产重组。 《预案》披露兮璞材料的主要盈利模式为"定制化代工+自主生产"相结合。截 3月3日，浙江向日葵大健康科技股份有限公司公告：3 月 2 日，公司及相关当事人收到浙江证监局出 具的《行政处罚事先告知书》。公司及相关责任人 ...

Group 1 - The company Sunflower (300111) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations of information disclosure laws [2] - Investors who purchased the stock between September 22, 2025, and December 25, 2025, and held it after the market closed on December 25, 2025, are eligible to apply for compensation for their losses [2] Group 2 - The company announced the termination of its plan to acquire 100% equity of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a share issuance and cash payment [4] - The CSRC's inquiry highlighted that Xipu Materials, based in Fujian Zhangzhou, has no actual production capacity at its factories in Zhangzhou and Lanzhou, despite being a core supplier for several wafer fabs [4] - The inquiry also requested detailed information on Xipu Materials' production capacity, including the status of approvals, construction, and production at its factories [4] Group 3 - Xipu Materials is primarily engaged in the research, manufacturing, and sales of high-end semiconductor materials, with core products including high-purity electronic gases and silicon-based precursors [5] - The inquiry requested financial details regarding Xipu Materials' revenue, costs, and gross margins for 2023 and 2024, as well as information on its transactions with Shanghai Deen Hong New Materials Technology Co., Ltd. [5] - Concerns were raised about potential adverse impacts on competition and independence due to the restructuring, as well as the legal issues faced by Xipu Materials' actual controller, which could affect asset transfers [5]

Core Viewpoint - The company Sunflower is under investigation by the Zhejiang Securities Regulatory Bureau for allegedly misleading statements in its restructuring plan, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, the company received a notice from the China Securities Regulatory Commission (CSRC) regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The investigation is based on the restructuring plan disclosed by the company in September 2025, which involved acquiring 100% of the shares of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of the shares of Zhejiang Beid Pharmaceutical Co., Ltd. [3]. - The CSRC's investigation aims to maintain order in the mergers and acquisitions market following the discovery of misleading statements in the restructuring proposal [1]. Group 2: Restructuring Plan and Business Model - The restructuring plan aimed to expand the company's business into the high-end semiconductor materials sector, which was expected to create a new growth curve and accelerate the transition to new productive forces [3]. - The targeted company, Xipu Materials, is involved in the research, manufacturing, and sales of high-end semiconductor materials, with products used in key processes of semiconductor manufacturing [3]. - Concerns have been raised regarding the actual production capacity of Xipu Materials' factories, which reportedly do not possess operational capabilities [5]. Group 3: Financial Performance and Market Reaction - In the first three quarters of 2025, the company reported revenue of 19.952 million yuan, a year-on-year decline of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [7]. - Following the announcement of the investigation, the company's stock price fell by 20% to 4.96 yuan per share, resulting in a total market capitalization of 6.385 billion yuan [7].

Core Viewpoint - The company Sunflower Health Technology Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements in its restructuring proposal, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, the company received a notice from the CSRC regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The investigation is based on the restructuring proposal disclosed on September 22, 2025, which involved acquiring 100% equity of Zhangzhou Xipu Material Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. [3]. - The CSRC's investigation aims to maintain order in the mergers and acquisitions market following the discovery of potentially misleading statements in the restructuring proposal [1][2]. Group 2: Business Overview - Sunflower primarily focuses on the pharmaceutical sector, developing, manufacturing, and selling drugs related to anti-infection, cardiovascular, and digestive systems [2][3]. - The restructuring proposal aimed to expand the company's business into the high-end semiconductor materials sector, which was expected to create a second growth curve and accelerate the transition to new productive forces [3]. Group 3: Market Reaction and Financial Performance - Following the announcement of the investigation, the company's stock price fell by 20% to 4.96 yuan per share, resulting in a total market capitalization of 6.385 billion yuan [5]. - The company's financial performance has been under pressure, with a reported revenue of 19.952 million yuan for the first three quarters of 2025, a year-on-year decline of 12.09%, and a net profit of 1.3062 million yuan, down 53.10% year-on-year [5].

Core Viewpoint - Zhejiang Sunflower (向日葵) is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements in its restructuring plan, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, Zhejiang Sunflower received a notice from the CSRC regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The company announced the termination of its asset restructuring plan, stating it no longer meets the conditions for issuing shares to purchase assets following the CSRC's notice [2][3]. Group 2: Business Overview - Zhejiang Sunflower focuses on the pharmaceutical sector, primarily engaged in the research, manufacturing, and sales of drugs for infections, cardiovascular diseases, and digestive systems [2]. - The restructuring plan aimed to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., intending to expand into the high-end semiconductor materials sector [3]. Group 3: Market Reaction and Financial Performance - Following the announcement of the investigation, Zhejiang Sunflower's stock price fell by 20%, closing at 4.96 yuan per share, with a total market capitalization of 6.385 billion yuan [5]. - The company's financial performance has been under pressure, with a reported revenue of 19.952 million yuan for the first three quarters of 2025, a year-on-year decline of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [5].

Core Viewpoint - The company Sunflower (SZ300111) has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to the termination of its planned asset acquisition and a significant drop in its stock price [2][6][9]. Group 1: Company Announcement and Stock Impact - On January 14, the company announced it received a notice from the CSRC regarding an investigation into information disclosure violations, resulting in the termination of its planned acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [2][9] - Following the announcement, the company's stock opened with a 20% limit down, with sell orders reaching 1.22 million shares [2]. - The stock price has halved from its peak of 10.28 yuan per share, closing at 4.96 yuan on January 15, with a total market capitalization of 6.385 billion yuan [2][10]. Group 2: Financial Performance - The company focuses on the pharmaceutical sector, specializing in the research, production, and sales of drugs for infections, cardiovascular diseases, and digestive systems [3]. - In the first three quarters of 2025, the company reported revenue of 200 million yuan, a year-on-year decrease of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [3]. Group 3: Acquisition Details and Regulatory Concerns - The planned acquisition involved purchasing 100% of Xipu Materials, which specializes in high-end semiconductor materials, and raising matching funds through share issuance [4]. - Concerns were raised regarding the actual production capacity of Xipu Materials, with media and regulatory scrutiny questioning the operational status of its facilities [4][5]. - The company was required to clarify the production capacity and operational status of its facilities by December 29, 2025, but failed to provide a response by January 15, 2026 [5]. Group 4: Investigation and Future Implications - The CSRC's investigation was prompted by market doubts about the acquisition's viability and potential misleading statements in the restructuring proposal [6][9]. - The company stated that its ongoing operations would not be significantly affected by the investigation or the termination of the acquisition [10]. - Legal experts noted that misleading statements could lead to significant consequences for investor trust and potential claims for damages from affected investors [10].

Core Viewpoint - The company Sunflower (SZ300111) has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to the termination of its planned asset acquisition and restructuring efforts [1][4][7]. Group 1: Investigation and Regulatory Actions - On January 14, the CSRC issued a notice to Sunflower regarding an investigation into the company's information disclosure practices, resulting in a formal case being opened [1][4]. - The company was required to halt its planned acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. due to the investigation [1][7]. - The Shenzhen Stock Exchange raised concerns about the actual production capacity of the acquisition target, Xipu Materials, prompting further scrutiny and a request for additional information from Sunflower [2][3]. Group 2: Financial Impact and Market Reaction - Following the announcement of the investigation, Sunflower's stock price fell to a limit down of 20%, with a trading volume of 1.22 million shares on January 15 [1][7]. - The company's stock price has halved from its peak of 10.28 yuan per share, reflecting significant market volatility and investor concern [1][8]. - Sunflower reported a revenue of 200 million yuan for the first three quarters of 2025, a year-on-year decrease of 12.09%, and a net profit of 1.31 million yuan, down 53.10% year-on-year, indicating financial pressures [1]. Group 3: Business Strategy and Future Outlook - Sunflower aimed to diversify into the semiconductor materials sector due to challenges in its core pharmaceutical business, which has been affected by price declines and competitive bidding risks [7][8]. - Despite the ongoing investigation, the company stated that its production and operational activities remain normal and that the termination of the restructuring will not significantly impact its operations [8].

Core Viewpoint - The company Sunflower is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to the termination of its semiconductor cross-border restructuring plan [1][5][21]. Group 1: Investigation and Impact - Sunflower's stock opened with a 20% limit down, currently priced at 4.96 yuan, with a total market value of 6.385 billion yuan [2]. - The company's stock has retraced over 40% from its peak last year [3]. - The CSRC issued a notice of investigation on January 14, 2026, due to misleading statements regarding the actual production capacity and business model of the restructuring targets [5][9]. Group 2: Restructuring Attempts - The planned restructuring involved acquiring 100% of Xipu Materials and 40% of Beid Pharmaceutical, with the intention to raise funds through a share issuance to specific investors [8]. - The restructuring plan was terminated following the CSRC's investigation, which deemed the proposal as containing misleading statements [8][21]. - This marks the end of Sunflower's attempt to transition into the semiconductor industry, which was seen as a significant shift from its previous focus on pharmaceuticals [10][21]. Group 3: Historical Context - Sunflower has attempted four cross-border transitions since its establishment, with only the first being successful [22]. - The company originally focused on crystalline silicon solar cells but shifted to pharmaceuticals in 2019 due to market pressures [23]. - Recent attempts to return to the solar industry and enter the metal-based ceramic materials sector were unsuccessful due to funding issues and unmet technical standards [24]. Group 4: Financial Performance - Sunflower has struggled near the breakeven point in recent years, with revenues of 297 million yuan, 336 million yuan, 338 million yuan, and 330 million yuan from 2021 to 2024, and fluctuating net profits [25]. - In the first half of 2025, the company reported a revenue of 144 million yuan, a year-on-year decline of 8.33%, and a net profit of 1.1607 million yuan, down 35.68% [25]. - For the first three quarters of 2025, revenue was 200 million yuan, a 12.09% decrease year-on-year, with a net profit of 1.3062 million yuan, down 53.10% [25].

Core Viewpoint - The company Sunflower is under investigation by the Zhejiang Securities Regulatory Bureau for misleading statements in its restructuring plan, which has led to a significant drop in its stock price by 10.01% on January 14 [1][2]. Group 1: Restructuring Plan - Sunflower plans to acquire 100% equity of Zhangzhou Xipu Material Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1][2]. - Xipu Material focuses on the research, manufacturing, and sales of high-end semiconductor materials, including high-purity electronic special gases and silicon-based precursors, which are essential in semiconductor manufacturing processes [1][2]. Group 2: Regulatory Concerns - The Zhejiang Securities Regulatory Bureau has initiated an investigation due to concerns over the actual production capacity and business model of the restructuring target, Xipu Material, which may involve misleading statements in the restructuring proposal [1][3]. - The Shenzhen Stock Exchange has issued a letter of concern regarding the restructuring, questioning the actual production capacity of Xipu Material's factories and requiring clarification on the accuracy of the proposal [3]. Group 3: Market Implications - The investigation signifies major challenges for Sunflower's cross-industry acquisition plans, potentially impacting its stock price and corporate reputation [3]. - The situation serves as a warning to other companies considering similar operations, emphasizing the importance of transparent and accurate information disclosure during asset restructuring [3].

Group 1 - The China Securities Regulatory Commission (CSRC) has launched an investigation into Sunflower's restructuring plan due to suspected misleading statements [2][3] - Sunflower's main business focuses on the pharmaceutical sector, including the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [3][4] - The company plans to acquire 100% of Zhuhai Xipu Materials Technology Co., Ltd. through a combination of issuing shares and cash payments, marking a shift towards the high-end semiconductor materials sector [4][5] Group 2 - Concerns have been raised regarding the actual production capacity of Xipu Materials' factories, which reportedly do not have operational capacity and have discrepancies with the restructuring proposal [5][6] - The Shenzhen Stock Exchange has issued a letter of inquiry to Sunflower, requesting clarification on four core issues related to Xipu Materials' production capacity, financial performance, potential competition, and legal issues concerning its actual controller [7][8] - Sunflower has not yet disclosed its response to the inquiry from the Shenzhen Stock Exchange [9]